Clinical trials: Chorionic Villus Sampling
Hereditary Diseases
Cell-based Non-invasive Prenatal Testing as an Alternative to Invasive Chorionic Villus Sampling
The study aims to evaluate cell-based non-invasive prenatal testing (cbNIPT) as an alternative to invasive chorionic villus sampling (CVS) in patients who achieve pregnancy following preimplantation genetic testing for hereditary…
- Trial name
- NCT05453474
- Testing
- Whole genome amplification
- Where
- Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Aalborg University Hospital
Prenatal Diagnoses, Preimplantation Genetic Diagnosis
Cell Based Non Invasive Prenatal Testing as an Alternative to Chorionic Villus Sampling Following Preimplantation Genetic Testing
The study aims to investigate whether cell-based non-invasive prenatal testing (cbNIPT) can be used as an alternative to invasive chorionic villus sampling (CVS) in patients who achieve pregnancy following preimplantation genetic…
- Trial name
- NCT04584047
- Testing
- Cell-based non-invasive prenatal testing
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Aalborg University Hospital
Amniocentesis, Chorionic Villus Sampling
Multımedia Information Before Amniocentesıs And Chorion Villus Sampling
It is known that the anxiety levels of pregnant women are high before amniocentesis and chorionic villus sampling and it is often neglected.
- Trial name
- NCT06572436
- Testing
- Multimedia information training
- Volunteers
- 90 people
- Sponsor
- Akdeniz University
Down Syndrome, Aneuploidy
Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies
To collect samples for the purpose of developing and optimizing an in vitro noninvasive prenatal diagnostic (NIPD) test. The NIPD test employs circulating cell free (ccff) DNA extracted from whole blood samples collected from…
- Trial name
- CHARMM-AP (NCT01052688)
- Testing
- Maternal blood draw of 30 to 50ml
- Where
- 10 sites in United States
- Volunteers
- 150 people
- Sponsor
- Sequenom, Inc.